Skip to main content

Table 3 The association between bcl-2 and other markers

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

  

Bcl-2 expression

P

  

(-)

(+)

 

Histology

ductal

55 (39.9)

83 (60.1)

0.521

 

others

4 (30.8)

9 (69.2)

 

Histologic grade

I, II

14 (21.2)

52 (78.8)

< 0.001

 

III

42 (54.5)

35 (45.5)

 

Endolymphatic tumor emboli

absent

2 (33.3)

4 (66.7)

1.000

 

present

43 (37.1)

73 (62.9)

 

ER

(-)

52 (76.5)

16 (23.5)

< 0.001

 

(+)

7 (8.4)

76 (91.6)

 

PR

(-)

55 (59.8)

37 (40.2)

< 0.001

 

(+)

4 (6.8)

55 (93.2)

 

p53

≤25%

33 (31.4)

72 (68.6)

0.004

 

>25%

26 (56.5)

20 (43.5)

 

c-erbB2

(-)~(2+)

42 (34.7)

79 (65.3)

0.027

 

(3+)

17 (56.7)

13 (43.3)

 

Ki-67

< 5%

18 (26.9)

49 (73.1)

0.006

 

≥5%

41 (48.8)

43 (51.2)

 
  1. n (%) patients for each variable. P-values were obtained using the chi-square test.